Published by
The Street
The Street
By Martin Baccardax Merck is reportedly eying cancer drug specialists Seagen as it looks to replace revenue from its Keytruda blockbuster, which loses patent exclusivity in 2028. Seagen (SGEN) – Get Seagen Inc. Report shares powered higher Thursday following a report from the Wall Street Journal that it’s in advanced takeover talks with drugmaker Merck & Co. (MRK) – Get Merck & Company Inc. Report that could value the cancer specialist at around $40 billion. The Journal said Merck and Seagen are looking towards a $200 per share price for the Bothell, Washington-based group, and hope to unveil …
Share this Story
